Cinacalcet and primary hyperparathyroidism: systematic review and meta regression

Ng, Cheng Han; Chin, Yip Han; Tan, Hon Qin Marcus; Ng, Jun Xuan; Yang, Samantha Peiling; Kiew, Jolene Jiayu; Khoo, Chin Meng

doi:10.1530/ec-20-0221

Cited by 24 publications

(14 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data was extracted and analyzed using the metaprop and metareg functions on STATA (16.1 StataCorp LLC, Texas, TX, USA) [ 23 , 24 , 25 ]. The meta-analysis of proportions was conducted using a Freeman–Turkey double arcsine transformation for the stabilization of variance, and the Dersimonian and Laird random effects model [ 26 ] was used for the pooled analysis.…”

Section: Methodsmentioning

confidence: 99%

A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity

Tan

Wong

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) recurrence after liver transplant is associated with a poor prognosis and significantly increases morbidity and mortality among liver transplant patients. Therefore, this meta-analysis aims to evaluate the overall prevalence of HCC recurrence following liver transplant. Medline and Embase databases were searched, and a meta-analysis of proportions was conducted. Observational studies reporting the prevalence of recurrent hepatocellular carcinoma (HCC) after liver transplant were included, with the analysis being stratified by adherence to Milan criteria, ethnicity, socio-economic status, alpha fetoprotein (AFP) levels, living donor vs. deceased donor, and the underlying aetiology of the liver disease. A meta-regression on the date of the study completion was also performed. Of a total 40,495 patients, 3888 developed an HCC recurrence. The overall prevalence of recurrent HCC was 13% (CI: 0.12–0.15). Patients beyond the Milan criteria (MC) were more likely to recur than patients within MC. Asian populations had the greatest prevalence of HCC recurrence (19%; CI: 0.15–0.24) when compared to Western (12%; CI: 0.11–0.13) and Latin American populations (11%; CI: 0.09–0.14). The prevalence of recurrent HCC was the highest in patients infected with hepatitis B virus (HBV) (18%; CI: 0.11–0.27) compared to other aetiologies. A higher AFP also resulted in an increased recurrence. This highlights interesting differences based on ethnicity, income, and aetiology, and further studies are needed to determine the reasons for the disparity.

show abstract

Section: Methodsmentioning

confidence: 99%

A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity

Tan

Wong

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, calcimimetic therapy has increasingly been reported to be useful in improving preoperative biochemical parameters in pHPT even before the COVID-19 pandemic [ 12 , 15 ]. The drop in efficacy of this therapy, and sometimes its biochemical normalization, was reported in the results of a randomized controlled study and a systemic review [ 16 , 17 ].…”

Section: Discussionmentioning

confidence: 99%

The Effect of the Frequently Used Cinacalcet for pHPT during the COVID-19 Pandemic on Perioperative Decrease in Parathyroid Hormone

Radulova-Mauersberger

Keßler

Keßler³

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Cinacalcet is a calcimimetic drug that has increasingly been used as a bridging therapy for primary hyperparathyroidism (pHPT), especially during the COVID-19 pandemic. The aim of our study was to investigate if preoperative cinacalcet therapy affects intraoperative parathyroid hormone (IOPTH) monitoring during parathyroidectomy, which is an important indicator for the success of surgery. Methods: In this single-center retrospective analysis, we studied the outcomes of 72 patients who underwent surgery for pHPT. We evaluated two groups: those with cinacalcet therapy before operation—the cinacalcet group (CG)—and those without medical therapy preoperatively (non-CG). In order to perform a between-group comparison of time trends, we fit a linear mixed-effects model with PTH as the response variable and predictors PTH levels preoperatively, group (cinacalcet yes/no), time, the group-by-time interaction, and a random intercept (per subject). Results: Our cohort included 51 (71%) women and 21 (29%) men, who were operated upon for pHPT in the period from January 2018 until August 2021. All patients were diagnosed with pHPT and 54% of the cohort were symptomatic for hypercalcemia. Moreover, 30% of the patients were treated with cinacalcet as a bridging therapy preoperatively, and this increased during the COVID-19 pandemic, as 64% of this group were treated in the last two years. Calcium values were significantly different before (p < 0.001) and after (p = 0.0089) surgery, but calcium level change did not differ significantly between the CG and non-CG. Parathyroid hormone (PTH) levels dropped significantly in both groups during 10 min IOPTH monitoring (p < 0.001), but there was no significant difference between the two groups (p = 0.212). Conclusions: In the examined patient cohort, the use of cinacalcet did not affect the value of IOPTH monitoring during surgery for pHPT.

show abstract

“…The majority of the studies were prospective and retrospective cohort studies. Four RCTs against placebo were also included, describing the use and efficacy of cinacalcet in a total of 722 PHPT patients [ 88 ]. Meta-regression reported a normalization rate of serum calcium of 90% (CI 0.82–0.96), with a mean reduction in calcium levels of 0.412 mmol/L (CI 0.343–0.481 mmol/L) from baseline.…”

Section: Pharmacologic Interventionmentioning

confidence: 99%

Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management

Dandurand

Ali

Khan

2021

JCM

View full text Add to dashboard Cite

Primary hyperparathyroidism (PHPT) is the most common cause of hypercalcemia in the outpatient setting. Symptomatic presentation includes non-specific signs and symptoms of hypercalcemia, skeletal fragility, nephrolithiasis and nephrocalcinosis. The majority of individuals present at an asymptomatic stage following routine biochemical screening, without any signs or symptoms of calcium or parathyroid hormone (PTH) excess or target organ damage. Indications for surgery have recently been revised as published in recent guidelines and consensus statements. Parathyroidectomy is advised in patients younger than 50 years old and in the presence of either significant hypercalcemia, impaired renal function, renal stones or osteoporosis. Surgery is always appropriate in suitable surgical candidates, however, medical management may be considered in those with mild asymptomatic disease, contraindications to surgery or failed previous surgical intervention. We summarized the optimal medical interventions available in the care of PHPT patients not undergoing parathyroidectomy. Calcium and vitamin D intake should be optimized. Antiresorptive therapy may be used for skeletal protection in patients with an increased fracture risk. Cinacalcet, a calcimimetic agent, has been shown to effectively lower serum calcium and PTH levels. The effect of medical treatment on the reduction in fracture risk is unknown and should be the focus of future research.

show abstract

Cinacalcet and primary hyperparathyroidism: systematic review and meta regression

Cited by 24 publications

References 58 publications

A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity

A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity

The Effect of the Frequently Used Cinacalcet for pHPT during the COVID-19 Pandemic on Perioperative Decrease in Parathyroid Hormone

Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management

Contact Info

Product

Resources

About